Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: BK virus-associated nephropathy (BKVAN) is an important cause of allograft dysfunction in kidney transplant recipients. It has an unfavorable clinical course, and no definite treatment guidelines have yet been established. Here, we report our center’s experience with biopsy-proven BKVAN and investigate factors associated with its progression. Methods: From January 2004 to April 2013, 25 patients with BKVAN were diagnosed by biopsy at Seoul St. Mary’s Hospital. Of the 25 patients, 10 were deceaseddonor transplant recipients and 15 were living-donor transplant recipients. Three of the patients underwent retransplantation. The primary immunosuppressant used was tacrolimus in 17 patients and cyclosporine in eight patients. Results: BKVAN was observed at a mean duration of 22.8 ± 29.1 months after transplantation. The mean serum creatinine level at biopsy was 2.2 ± 0.7 mg/dL. BKVAN occurred with acute rejection in eight patients (28%). Immunosuppression modification was performed in 21 patients (84%). Additionally, leflunomide and intravenous immunoglobulin were administered to 13 patients (52%) and two (8%), respectively. Allograft loss occurred in five patients (27.8%) during the follow- up period at 0.7, 17.1, 21.8, 39.8, and 41.5 months after the BKVAN diagnosis. Advanced stages of BKVAN, increased creatinine levels, and accompanying acute rejection at the time of BKVAN diagnosis increased the risk of allograft failure. Conclusions: The clinical outcomes in patients with biopsy-proven BKVAN were unfavorable in the present study, especially in patients with advanced-stage BKVAN, poor renal function, and acute allograft rejection.
Abstract
Background/Aims: BK virus-associated nephropathy (BKVAN) is an important cause of allograft dysfunction in kidney transplant recipients. It has an unfavorable clinical course, and no definite treatment guidelines have yet been established. Here, we report our center’s experience with biopsy-proven BKVAN and investigate factors associated with its progression. Methods: From January 2004 to April 2013, 25 patients with BKVAN were diagnosed by biopsy at Seoul St. Mary’s Hospital. Of the 25 patients, 10 were deceaseddonor transplant recipients and 15 were living-donor transplant recipients. Three of the patients underwent retransplantation. The primary immunosuppressant used was tacrolimus in 17 patients and cyclosporine in eight patients. Results: BKVAN was observed at a mean duration of 22.8 ± 29.1 months after transplantation. The mean serum creatinine level at biopsy was 2.2 ± 0.7 mg/dL. BKVAN occurred with acute rejection in eight patients (28%). Immunosuppression modification was performed in 21 patients (84%). Additionally, leflunomide and intravenous immunoglobulin were administered to 13 patients (52%) and two (8%), respectively. Allograft loss occurred in five patients (27.8%) during the follow- up period at 0.7, 17.1, 21.8, 39.8, and 41.5 months after the BKVAN diagnosis. Advanced stages of BKVAN, increased creatinine levels, and accompanying acute rejection at the time of BKVAN diagnosis increased the risk of allograft failure. Conclusions: The clinical outcomes in patients with biopsy-proven BKVAN were unfavorable in the present study, especially in patients with advanced-stage BKVAN, poor renal function, and acute allograft rejection.
참고문헌 (26)
- Hirsch HH., "Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation", Am J Transplant, 2, pp.25~30 (2002)
- Costa C, "Monitoring of BK virus replication in the first year following renal transplantation", Nephrol Dial Transplant, 23, pp.3333~3336 (2008)
- Nickeleit V, "Polyomavirus nephropathy:morphology, pathophysiology, and clinical management", Curr Opin Nephrol Hypertens, 12, pp.599~605 (2003)
- Hirsch HH, "Polyomavirus-associated nephropathy in renal transplantation:interdisciplinary analyses and recommendations", Transplantation, 79, pp.1277~1286 (2005)
- Hirsch HH, "Polyomavirus BK", Lancet Infect Dis, 3, pp.611~623 (2003)
- Purighalla R, "BK virus infection in a kidney allograft diagnosed by needle biopsy", Am J Kidney Dis, 26, pp.671~673 (1995)
- 이상오, "고형장기이식 환자에서 흔히 보는 감염", 대한내과학회지, 84(2), pp.145~157 (2013), 대한내과학회[DOI]
- 정병하, "Changing Donor Source Pattern for Kidney Transplantation over 40 Years: A Single-Center Experience", The Korean Journal of Internal Medicine, 25(3), pp.288~293 (2010), 대한내과학회
- Chung BH, "Clinical usefulness of BK virus plasma quantitative PCR to prevent BK virusassociated nephropathy", Transpl Int, 25, pp.687~695 (2012)
- Hurault de Ligny B, "Polyomavirus-induced acute tubulo-interstitial nephritis in renal allograft recipients", Transplant Proc, 32, pp.2760~2761 (2000)
- Ahuja M, "Polyoma virus infection after renal transplantation: use of immunostaining as a guide to diagnosis", Transplantation, 71, pp.896~899 (2001)
- Barri YM, "Polyoma viral infection in renal transplantation: the role of immunosuppressive therapy", Clin Transplant, 15, pp.240~246 (2001)
- Hirsch HH, "Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy", J Infect Dis, 184, pp.1494~1495 (2001)
- Hirsch HH, "Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients", N Engl J Med, 347, pp.488~496 (2002)
- Babel N, "Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples", Transplantation, 88, pp.89~95 (2009)
- Viscount HB, "Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy", Transplantation, 84, pp.340~345 (2007)
- Randhawa P, "BK virus infection in transplant recipients: an overview and update", Am J Transplant, 6, pp.2000~2005 (2006)
- Wiseman AC., "Polyomavirus nephropathy: a current perspective and clinical considerations", Am J Kidney Dis, 54, pp.131~142 (2009)
- Toupance O, "Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses", Transpl Int, 13, pp.413~419 (2000)
- Ohashi K, "Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex", J Immunol, 164, pp.558~561 (2000)
- Kang YN, "BK virus infection in renal allograft recipients", Transplant Proc, 35, pp.275~277 (2003)
- Mengel M, "Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs", Nephrol Dial Transplant, 18, pp.1190~1196 (2003)
- Drachenberg CB, "Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load", Am J Transplant, 4, pp.2082~2092 (2004)
- Kiberd BA., "Screening to prevent polyoma virus nephropathy:a medical decision analysis", Am J Transplant, 5, pp.2410~2416 (2005)
- Randhawa P, "Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients", J Clin Microbiol, 42, pp.1176~1180 (2004)
- 김윤정, "Impact of Combined Acute Rejection on BK Virus-Associated Nephropathy in Kidney Transplantation", Journal of Korean Medical Science, 28(12), pp.1711~1715 (2013), 대한의학회